Insulin-Like Growth Factors — Systemic & Localized Growth Variants
IGF-1 LR3 and IGF-1 DES are modified variants of Insulin-Like Growth Factor 1. LR3 has an extended half-life (20–30 hours) and acts systemically, while DES has a very short half-life (20–30 minutes) and acts locally at the injection site. Both drive muscle hypertrophy and recovery.
Advanced Compound
IGF-1 variants are NOT for beginners. These are potent growth factors requiring experienced prescriber oversight, careful dosing, and metabolic monitoring.
Binds IGF-1 receptors to stimulate muscle cell proliferation (hyperplasia) and protein synthesis. LR3 circulates systemically with prolonged receptor activation. DES acts locally with intense but brief receptor binding at the injection site.
| Parameter | Details |
|---|---|
| Starting Dose | 25 mcg post-workout |
| Moderate Dose | 50 mcg post-workout |
| High Dose | 100 mcg post-workout |
| Half-Life | 20–30 hours (systemic) |
| Route | Bilateral injection into trained muscle, post-workout |
| Cycle Length | 4–6 weeks |
| Parameter | Details |
|---|---|
| Starting Dose | 25 mcg immediately post-workout |
| Moderate Dose | 50 mcg immediately post-workout |
| High Dose | 100 mcg immediately post-workout |
| Half-Life | 20–30 minutes (very short, local action) |
| Route | Bilateral injection into trained muscle, immediately post-workout |
| Cycle Length | 4–6 weeks |
Hypoglycemia Risk
IGF-1 can cause significant blood sugar drops. Always have fast-acting carbohydrates available during and after injection. Do not use fasted.
Insulin Resistance Management
Running Berberine or a GDA alongside IGF-1 is strongly recommended to manage insulin sensitivity. Monitor fasting glucose throughout the cycle.
This guide is for educational and clinical-support purposes only. All dosing must be supervised by a licensed prescriber. Matrix Advanced Solutions does not provide medical advice. Always consult your healthcare provider before starting any peptide protocol.